May 28
|
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
|
May 20
|
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
|
May 20
|
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
|
May 8
|
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
|
May 7
|
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
|
May 7
|
bioAffinity Technologies Announces Closing of $3.25 Million Offering
|
May 7
|
BioAffinity Technologies announces pricing of $3.25M offering
|
May 6
|
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
|
May 6
|
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
|
May 6
|
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies
|
May 5
|
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa
|
Apr 7
|
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
|
Mar 13
|
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
|
Feb 6
|
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
|
Feb 6
|
The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity
|
Feb 5
|
Top Research Reports for Amazon.com, Bank of America & Caterpillar
|
Dec 17
|
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
|
Oct 9
|
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
|
Sep 18
|
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
|
Jun 12
|
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
|